Product Description
AstraZeneca is developing TACE (transarterial chemoembolization) as a transarterial therapy procedure for the treatment of hepatocellular carcinoma (HCC). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03778957)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Injection
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Ecuador | India | Ireland | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Russia, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 22
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Liver Cancer
Phase 2: Cholangiocarcinoma|Neuroendocrine Tumors
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06192784 |
CCGLC-012 | P2 |
Recruiting |
Cholangiocarcinoma |
2025-01-31 |
37% |
2024-03-27 |
Primary Endpoints|Treatments |
NCT02724540 |
UPCC 01215 | P2 |
Completed |
Neuroendocrine Tumors |
2024-04-30 |
19% |
2025-01-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06114082 |
IDADOX | P2 |
Recruiting |
Liver Cancer|Hepatocellular Carcinoma |
2025-12-31 |
12% |
2025-01-08 |
Primary Completion Date|Primary Endpoints |
NCT06995105 |
CISLD-13 | P2 |
Recruiting |
Hepatocellular Carcinoma |
2027-04-01 |
12% |
2025-05-31 |
Primary Endpoints|Treatments |
NCT05970666 |
23-OBU-FJ-HCC-II-012 | P2 |
Recruiting |
Hepatocellular Carcinoma |
2026-11-15 |
42% |
2024-02-29 |
Primary Endpoints|Treatments|Trial Status |
NCT05171335 |
PRO00028690 | P2 |
Enrolling by invitation |
Hepatocellular Carcinoma |
2026-06-30 |
63% |
2022-09-22 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT04472767 |
UCI 19-49 [HS# 2020-5807] | P2 |
Recruiting |
Hepatocellular Carcinoma |
2026-06-01 |
12% |
2024-03-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05319431 |
AK104-216 | P2 |
Active, not recruiting |
Hepatocellular Carcinoma |
2023-08-15 |
12% |
2025-03-13 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
NCT03397654 |
PETAL | P2 |
Completed |
Hepatocellular Carcinoma |
2023-02-01 |
12% |
2025-02-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
JapicCTI-205286 |
JapicCTI-205286 | P3 |
Active |
Hepatocellular Carcinoma |
2029-12-31 |
|||
jRCT2080225190 |
jRCT2080225190 | P3 |
Completed |
Hepatocellular Carcinoma |
2029-12-31 |
|||
NCT04712643 |
ML42612 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2029-02-01 |
73% |
2025-02-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT04246177 |
LEAP-012 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2028-06-30 |
62% |
2023-02-03 |
Primary Endpoints|Trial Status |
NCT05320692 |
SHR-1210-â ¢-336 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2026-07-30 |
39% |
2025-02-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments |
NCT05301842 |
EMERALD-3 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2025-12-31 |
70% |
2025-01-16 |
|
NCT05613478 |
2022-SR-558 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2025-11-01 |
12% |
2025-01-03 |
|
NCT06371157 |
AK104-308 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2025-10-25 |
32% |
2025-03-13 |
Primary Endpoints |
NCT04340193 |
CheckMate 74W | P3 |
Completed |
Liver Cancer |
2023-12-12 |
91% |
2024-11-27 |
|
NCT06882876 |
JS014-F01 | P1 |
Enrolling by invitation |
Hepatocellular Carcinoma |
2027-01-01 |
2025-09-20 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT03778957 |
EMERALD-1 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2023-09-11 |
74% |
2024-01-18 |
Primary Endpoints|Study Completion Date|Treatments |
NCT03143270 |
NCT03143270 | P1 |
Active, not recruiting |
Liver Cancer |
2026-04-01 |
50% |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT04220944 |
ZS-IR-2019B | P1 |
Active, not recruiting |
Hepatocellular Carcinoma |
2024-10-30 |
21% |
2024-08-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/18/2025 |
News Article |
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™ |
|
11/11/2025 |
News Article |
Interventional Oncology Market to Reach $4.38 Billion by 2030 at CAGR 8.55% - Grand View Research, Inc. |
|
11/10/2025 |
News Article |
Booking Health Announces Expanded Access to Stage 4 Lung Cancer Treatments During Lung Cancer Awareness Month |
|
11/10/2025 |
News Article |
Booking Health Launches Initiative to Improve Global Access to Stage 4 Pancreatic Cancer Treatment |